Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets

Journal of Medicinal Chemistry

Volumn 55, Issue 4, 2012, Pages 1731-1750

  Baud, Matthias G J ^a   Leiser, Thomas ^b   Haus, Patricia ^b   Samlal, Sharon ^c   Wong, Ai Ching ^c   Wood, Robert J ^c   Petrucci, Vanessa ^d   Gunaratnam, Mekala ^d   Hughes, Siobhan M ^a   Buluwela, Lakjaya ^a   Turlais, Fabrice ^c   Neidle, Stephen ^d   Meyer Almes, Franz Josef ^b   White, Andrew J P ^a   Fuchter, Matthew J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 BROMO 4 HYDROXYPHENYL) 2 (HYDROXYIMINO) N [2 (METHYLTHIO)ETHYL]PROPANAMIDE; 3 (3 BROMO 4 HYDROXYPHENYL) 2 (METHOXYIMINO) N [2 (METHYLTHIO)ETHYL]PROPANAMIDE; 3 (3 BROMO 4 METHOXYPHENYL) 2 (HYDROXYIMINO) N [2 (METHYLTHIO)ETHYL]PROPANAMIDE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; ENZYME INHIBITOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; N,N' (2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3 BROMO 4,5 DIMETHOXYPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' (2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3 BROMO 5 NITROPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' (2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3,4 DIMETHOXYPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' (2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3,5 DIBROMO 4 HYDROXYPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' (HEXANE 1,6 DIYL)BIS[3 (3 BROMO 4 HYDROXYPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[2 (HYDROXYIMINO) 3 (3 IODO 4,5 DIMETHOXYPHENYL)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[2 (HYDROXYIMINO) 3 (4 HYDROXYPHENYL)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[2 (HYDROXYIMINO) 3 [(3 IODO 4 METHOXYPHENYL)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[2 (HYDROXYIMINO) 3 [4 (METHYLTHIO)PHENYL]PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[2 (HYDROXYIMINO) 3 PHENYLPROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3 BROMO 4 HYDROXYPHENYL) 2 (METHOXYIMINO)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3 BROMO 4 METHOXYPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (3 BROMO 4 METHOXYPHENYL) 2 (METHOXYIMINO)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 (4 FLUOROPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 [(3 BROMO 4 FLUOROPHENYL) 2 (HYDROXYIMINO)PROPANAMIDE]; N,N' [2,2' DISULFANEDIYLBIS(ETHANE 2,1 DIYL)]BIS[3 [3 BROMO 4 (METHYLTHIO)PHENYL] 2 (HYDROXYIMINO)PROPANAMIDE]; OXIME; PSAMMAPLIN A; THIOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLATION; ARTICLE; CYTOTOXICITY; DNA METHYLATION; DRUG SYNTHESIS; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; SIMULATION; STRUCTURE ACTIVITY RELATION; UPREGULATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DISULFIDES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG SCREENING ASSAYS, ANTITUMOR; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; ISOENZYMES; MODELS, MOLECULAR; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TYROSINE;

EID: 84857429882     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2016182     Document Type: Article

References (80)

1. Watt, F.; Molloy, P. L. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter Genes Dev. 1988, 2, 1136-1143
2. Dong, A.; Yoder, J. A.; Zhang, X.; Zhou, L.; Bestor, T. H.; Cheng, X. Structure of human DNMT2, an enigmatic DNA methyltransferase homolog that displays denaturant-resistant binding to DNA Nucleic Acids Res. 2001, 29, 439-448 (Pubitemid 32062984)
3. Okano, M.; Xie, S.; Li, E. Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells Nucleic Acids Res. 1998, 26, 2536-2540 (Pubitemid 28297362)
4. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future Nature Rev. Drug Discovery 2006, 5, 37-50
5. Chedin, F.; Lieber, M. R.; Hsieh, C. L. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 16916-16921 (Pubitemid 36034073)
6. Chen, Z. X.; Mann, J. R.; Hsieh, C. L.; Riggs, A. D.; Chedin, F. J. Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family Cell Biochem. 2005, 95, 902-917 (Pubitemid 41420139)
7. Jia, D.; Jurkowska, R. Z.; Zang, X.; Jeltsch, A.; Cheng, X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation Nature 2007, 449, 248-251 (Pubitemid 47402375)
8. Kareta, M. S.; Botello, Z. M.; Ennis, J. J.; Chou, C.; Chedin, F. J. Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L J. Biol. Chem. 2006, 281, 25893-25902 (Pubitemid 44401795)
9. Bourc'his, D.; Xu, G. L.; Lin, C. S.; Bollman, B.; Bestor, T. H. Dnmt3L and the establishment of maternal genomic imprints Science 2001, 294, 2536-2539 (Pubitemid 34027291)
10. Bourc'his, D.; Bestor, T. H. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L Nature 2004, 431, 96-99 (Pubitemid 39215115)
11. Ooi, S. K. e. a. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA Nature 2007, 448, 714-717
12. Johnstone, R. W. Histone Deacetylase inhibitors: novel drugs for the treatment of cancer Nature Rev. Drug Discovery 2002, 1, 287-299 (Pubitemid 37361445)
13. Xu, W.; Parmigiani, R.; Marks, P. Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 2007, 26, 5541-5552 (Pubitemid 47255934)
14. Crabb, S.; Howell, M.; Rogers, H.; Ishfaq, M.; Yurek-George, A.; Carey, K.; Pickering, B.; East, P.; Mitter, R.; Maeda, S.; Johnson, P.; Townsend, P.; Shin-Ya, K.; Yoshida, M.; Ganesan, A.; Packham, G. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A Biochem. Pharmacol. 2008, 76, 463-475
15. Miller, T.; Witter, D.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46, 5097-5116 (Pubitemid 37414179)
16. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics-An epicenter of gene regulation: histones and histone-modifying enzymes Angew. Chem., Int. Ed. 2005, 44, 3186-3216 (Pubitemid 40778337)
17. Suzuki, T.; Miyata, N. Epigenetic control using natural products and synthetic molecules Curr. Med. Chem. 2006, 13, 935-958
18. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007, 25, 84-90 (Pubitemid 46087907)
19. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 2007, 12, 1247-1252 (Pubitemid 350106355)
20. Fang, M. Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C. S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines Cancer Res. 2003, 63, 7563-7570 (Pubitemid 37466673)
21. Lee, W. J.; Zhu, B. T. Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols Carcinogenesis 2006, 27, 269-277 (Pubitemid 43159879)
22. Li, Y.; Liu, L.; Andrews, L. G.; Tollefsbol, T. O. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms Int. J. Cancer 2009, 125, 286-296
23. Pina, I. C.; Gautschi, J. T.; Wang, G. Y. S.; Sanders, M. L.; Schmitz, F. J.; France, D.; Cornell-Kennon, S.; Sambucetti, L. C.; Remiszewski, S. W.; Perez, L. B.; Bair, K. W.; Crews, P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase J. Org. Chem. 2003, 68, 3866-3873 (Pubitemid 36576636)
24. Quinoa, E.; Crews, P. Phenolic constituents of Psammaplysilla Tetrahedron Lett. 1987, 28, 3229-3232
25. Arabshahi, L.; Schmitz, F. J. Brominated tyrosine metabolites from an unidentified sponge J. Org. Chem. 1987, 52, 3584-3586 (Pubitemid 17134134)
26. Rodriguez, A. D.; Akee, R. K.; Scheuer, P. J. Two bromotyrosine-cysteine derived metabolites from a sponge Tetrahedron Lett. 1987, 28, 4989-4992 (Pubitemid 18061530)
27. Kim, D.; Lee, I. S.; Jung, J. H.; Lee, C. O.; Choi, S. U. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells Anticancer Res. 1999, 19, 4085-4090
28. Kim, D.; Lee, I. S.; Jung, J. H.; Yang, S. I. Psammaplin A, a natural bromotyrosine derivative from a sponge, possesses the antibacterial activity against methicillin-resistant Staphylococcus aureus and the DNA gyrase-inhibitory activity Arch. Pharm. Res. 1999, 22, 25-29
29. Shin, J.; Lee, H. S.; Seo, Y.; Rho, J. R.; Cho, K. W.; Paul, V. J. New bromotyrosine metabolites from the sponge Aplysinella rhax Tetrahedron 2000, 56, 9071-9077
30. Tabudravu, J. N.; Eijsink, V. G. H.; Gooday, G. W.; Jaspars, M.; Komander, D.; Legg, M.; Synstad, B.; van Aalten, D. M. F. Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax Bioorg. Med. Chem. 2002, 10, 1123-1128 (Pubitemid 34139927)
31. Nicholas, G. M.; Eckman, L. L.; Ray, S.; Hughes, R. O.; Pfefferkorn, J. A.; Barluenga, S.; Nicolaou, K. C.; Bewley, C. A. Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-s-conjugate amidase Bioorg. Med. Chem. Lett. 2002, 12, 2487-2490 (Pubitemid 34879897)
32. Shim, J. S.; Lee, H. S.; Shin, J.; Kwon, H. J. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro Cancer Lett. 2004, 203, 163-169 (Pubitemid 38058684)
33. Jiang, Y.; Ahn, E.-Y.; Ryu, S. H.; Kim, D.-K.; Park, J.-S.; Yoon, H. J.; Yoo, S.; Lee, B.-J.; Lee, D. S.; Jung, J. H. Cytotoxicity of psammaplin A from a two-sponge association may correlate with the inhibition of DNA replication. BMC Cancer 2004, 4, doi: 10.1186/1471-2407-4-70 (Pubitemid 40180284)
34. Park, Y.; Liu, Y.; Hong, J.; Lee, C.-O.; Cho, H.; Kim, D.-K.; Im, K. S.; Jung, J. H. New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis J. Nat. Prod. 2003, 66, 1495-1498 (Pubitemid 37490402)
35. Nebbioso, A.; Pereira, R.; Khanwalkar, H.; Matarese, F.; Garcia-Rodriguez, J.; Miceli, M.; Logie, C.; Kedinger, V.; Ferrara, F.; Stunnenberg, H. G.; De Lera, A. R.; Gronemeyer, H.; Altucci, L. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor, UVI5008 Mol. Cancer Ther. 2011, 10, 2394-2404
36. Kim, D. H.; Shin, J.; Kwon, H. J. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase Exp. Mol. Med. 2007, 39, 47-55 (Pubitemid 46356005)
37. Garcia, J.; Franci, G.; Pereira, R.; Benedetti, R.; Nebbioso, A.; Rodriguez-Barrios, F.; Gronemeyer, H.; Altucci, L.; de Lera, A. R. Epigenetic profiling of the antitumor natural product psammaplin A and its analogues Bioorg. Med. Chem. 2011, 19, 3637-3649
38. Baud, M. G. J.; Leiser, T.; Meyer-Almes, F.-J.; Fuchter, M. J. New synthetic strategies towards Psammaplin A, access to natural product analogues for biological evaluation Org. Biomol. Chem. 2011, 9, 659-662
39. G- Hydroxyguanidines from primary amines Org. Lett. 2006, 8, 4035-4038
40. Siverstein, R. M.; Bassler, G. C.; Morill, T. C. Spectrometric Identification of Organic Compounds, 4 th ed.; Wiley: New York, 1981.
41. Kazlauskas, R.; Lidgard, R. O.; Murphy, P. T.; Wells, R. J.; Blount, J. F. Brominated tyrosine-derived metabolites from the sponge Ianthella basta Aust. J. Chem. 1981, 34, 765-786 (Pubitemid 11030716)
42. Yang, Q.; Liu, D.; Sun, D.; Yang, S.; Hu, G.; Wu, Z.; Zhao, L. Synthesis of the marine bromotyrosine psammaplin F and crystal structure of a psammaplin A Analogue Molecules 2010, 15, 8784-8795
43. Wang, D.; Helquist, P.; O., W. Zinc binding in HDAC inhibitors: A DFT study J. Org. Chem. 2007, 72, 5446-5449 (Pubitemid 47056245)
44. Guénin, E.; M., M.; Bouchemal, N.; Prangé, T.; Lecouvey, M. Syntheses of phosphonic esters of alendronate, pamidronate and neridronate Eur. J. Org. Chem. 2007, 3380-3391
45. Wegener, D.; Wirsching, F.; Riester, D.; Schwienhorst, A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening Chem. Biol. 2003, 10, 61-68 (Pubitemid 36154475)
46. Hildmann, C.; Ninkovic, M.; Dietrich, R.; Wegener, D.; Riester, D.; Zimmermann, T.; Birch, O. M.; Bernegger, C.; Loidl, P.; Schwienhorst, A. A new amidohydrolase from Bordetella or Alcaligenes Strain FB188 with similarities to histone deacetylases J. Bacteriol. 2004, 186, 2328-2339 (Pubitemid 38451836)
47. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. Crystal structure of a bacterial class 2 histone deacetylase homologue J. Mol. Biol. 2005, 354, 107-120 (Pubitemid 41527217)
48. Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P. T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Serafini, S.; Steinkuhler, C. A series of novel, potent, and selective histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 5948-5952 (Pubitemid 44755303)
49. Suzuki, T.; Miyata, N. Non-hydroxamate Histone Deacetylase inhibitors Curr. Med. Chem. 2005, 12, 2867-2880 (Pubitemid 41601562)
50. Wong, J. C.; Hong, R.; Schreiber, S. L. Structural biasing elements for in-cell Histone Deacetylase paralog selectivity J. Am. Chem. Soc. 2003, 125, 5586-5587 (Pubitemid 36592854)
51. Bressi, J. C.; Jennings, A. J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C. E.; Navre, M.; Gangloff, A. R. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl) benzamides Bioorg. Chem. Med. Chem. Lett. 2010, 20, 3142-3145
52. Saavedra, O. M.; Isakovic, L.; Llewellyn, D. B.; Zhan, L.; Bernstein, N.; Claridge, S.; Raeppel, F.; Vaisburg, A.; Elowe, N.; Petschner, A. J.; Rahil, J.; Beaulieu, N.; MacLeod, A. R.; Delorme, D.; Besterman, J. M.; Wahhab, A. SAR around (L)-S-adenosyl-L-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes Bioorg. Chem. Med. Chem. Lett. 2009, 19, 2747-2751
53. Kuck, D.; Singh, N.; Lyko, F.; Medina-Franco, J. L. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation Bioorg. Med. Chem. 2010, 18, 822-829
54. Posfai, J.; Bhagwat, A. S.; Posfai, G.; Roberts, R. J. Predictive motifs derived from cytosine methyltransferases Nucleic Acids Res. 1989, 17, 2421-2435 (Pubitemid 19103229)
55. Takiguchi, M.; Achanzar, W. E.; Qu, W.; Guying, L.; Waalkes, M. P. Effects of cadmium on DNA-(cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation Exp. Cell Res. 2003, 286, 355-365 (Pubitemid 36566447)
56. Godert, A. M.; Angelino, N.; Woloszynska-Read, A.; Morey, S. R.; James, S. R.; Karpf, A. R.; Sufrin, J. R. An improved synthesis of psammaplin A Bioorg. Med. Chem. Lett. 2006, 16, 3330-3333
57. Alao, J. P.; Stavropoulou, A. V.; Lam, E. W.-F.; Coombes, R. C.; Vigushin, D. M., Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol. Cancer 2006, 5, doi: 10.1186/1476-4598-5-8.
58. Huang, L.; Sowa, Y.; Sakai, T.; Pardee, A. B. Activation of the p21WAF1/CIP1 promoter independant of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites Oncogene 2000, 19, 5712-5719
59. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res. 2002, 62, 4916-4921 (Pubitemid 34984414)
60. Suzuki, T.; Nagano, Y.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-Based non-hydroxamates Bioorg. Med. Chem. Lett. 2003, 13, 4321-4326 (Pubitemid 37490811)
61. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317 (Pubitemid 38624614)
62. Suzuki, T.; Matsuura, A.; Kouketsu, A.; Hisakawa, S.; Nakagawa, H.; Miyata, N. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent Bioorg. Med. Chem. 2005, 13, 4332-4342 (Pubitemid 40779404)
63. Suzuki, T.; Matsuura, A.; Kouketsu, A.; Nakagawa, H.; Miyata, N. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design Bioorg. Med. Chem. Lett. 2005, 15, 331-335 (Pubitemid 39647145)
64. Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates J. Med. Chem. 2005, 48, 1019-1032 (Pubitemid 40270446)
65. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193 (Pubitemid 29436325)
66. Ficner, R. Novel structural insights into class I and II histone deacetylases Curr. Top. Med. Chem. 2009, 9, 235-240
67. Karpf, A. R.; Lasek, A. W.; Ririe, T. O.; Hanks, A. N.; Grossman, D.; Jones, D. A. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine Mol. Pharmacol. 2004, 65, 18-27 (Pubitemid 38113882)
68. Remiszewski, S. W. The discovery of NVP-LAQ824: from concept to clinic Curr. Med. Chem. 2003, 10, 2393-2402 (Pubitemid 37236395)
69. Ahn, M. Y.; Jung, J. H.; Na, Y. J.; Kim, H. S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells Gynecol. Oncol. 2008, 108, 27-33 (Pubitemid 350299431)
70. Zhu, Y.; Wei, Q.; Lu, Y.; Yao, J.; Cao, X. Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells Mol. Med. Rep. 2009, 2, 743-747
71. Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Hugo, H.; Moasser, M.; Minton, S. E. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Br. J. Cancer 2011, 104, 1828-1835
72. Amundsen, A. R.; Whelan, J.; Bosnich, B. Biological analogues. On the nature of the binding sites of copper-containing proteins J. Am. Chem. Soc. 1977, 99, 6730-6739
73. Volund, A. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models Biometrics 1978, 34, 357-365 (Pubitemid 9016007)
74. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J Natl. Cancer Inst. 1990, 82, 1107-1112 (Pubitemid 20213250)
75. Arnold, K.; Bordoli, L.; Kopp, J.; T., S. The Swiss-Model workspace: a web-based environment for protein structure homology modelling Bioinformatics 2006, 22, 195-201 (Pubitemid 43205406)
76. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graphics Model. 2006, 25, 247-260 (Pubitemid 44363172)
77. Lang, P. T.; Brozell, S. R.; Mukherjee, S.; Pettersen, E. F.; Meng, E. C.; Thomas, V.; Rizzo, R. C.; Case, D. A.; James, T. L.; Kuntz, I. D. DOCK 6: Combining techniques to model RNA-small molecule complexes RNA 2009, 15, 1219-1230
78. Graves, A. P.; Shivakumar, D. M.; Boyce, S. E.; Jacobson, M. P.; Case, D. A.; Shoichet Rescoring docking hit lists for model cavity sites: predictions and experimental testing J. Mol. Biol. 2008, 377, 914-934
79. Hess, B.; Kutzner, C.; Van der Spoel, D.; Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 2008, 4, 435-447
80. Sorin, E. J.; Pande, V. S. Exploring the helix-coil transition via all-atom equilibrium ensemble simulations Biophys. J. 2005, 88, 2472-2493 (Pubitemid 40976118)